Collagen Peptides Help Mice and Humans Perform Better at High Altitude

Two-stage study: (1) Animal stage — mice received BCP for 5 days then performed rotarod tests at simulated 4,000 m altitude. (2) Human stage — volunteers took BCP supplementation and exercised in a hypobaric hypoxic chamber, with SpO2 and performance measures recorded. Peptide characterization included amino acid analysis, dynamic light scattering for particle size, FT-IR spectroscopy for structure confirmation, and in vitro antioxidant assays.

Millions of people travel to or live at high altitudes where reduced oxygen can cause altitude sickness, fatigue, and impaired performance. Finding a safe, food-grade supplement that improves hypoxia tolerance could benefit athletes training at altitude, military personnel, high-altitude workers, and travelers. Collagen peptides are already widely consumed supplements, making translation to practical use straightforward.

Collagen peptides are among the most popular dietary supplements globally, primarily marketed for skin, joint, and bone health. This study opens a new application area — altitude and hypoxia performance — which could expand the collagen peptide market significantly. The combination of animal and human evidence in a single study also raises the evidence bar compared to the many collagen studies that rely on only one model.

The abstract contains truncated statistical data (incomplete p-values and measure descriptions), making it difficult to fully assess the human trial results. The mouse supplementation period was only 5 days, and longer-term effects are unknown. The human trial details (sample size, blinding, control treatment) are not fully described in the abstract. The mechanisms linking antioxidant activity to hypoxia tolerance are correlational, not causally established.